Clinical Trials Logo

Resectable Biliary Tract Cancer clinical trials

View clinical trials related to Resectable Biliary Tract Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT05640791 Recruiting - Clinical trials for Resectable Biliary Tract Cancer

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Start date: December 1, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well gemcitabine, cisplatin, nab-paclitaxel and durvalumab work before surgery in treating participants with Biliary Tract Cancer. The international multicenter phase III clinical study TOPAZ-1 has confirmed that durvalumab combined with gemcitabine and cisplatin can bring survival benefits to advanced BTC. Drugs used in chemotherapy, such as nab-paclitaxel, cisplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy and Durvalumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

NCT ID: NCT03768531 Withdrawn - Clinical trials for Resectable Biliary Tract Cancer

Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer

Start date: June 14, 2019
Phase: Phase 2
Study type: Interventional

The purposed of this research is to study the safety and clinical activity of the combination of nivolumab and cabiralizumab in people with resectable biliary tract cancers (BTC).